OrthoPediatrics Corp. (KIDS)

In the past six months, OrthoPediatrics Corp.'s stock price has been impacted by several events. The company reported record total annual revenue of $236.3 million for full year 2025, up 15% from 2024, and Q4 2025 revenue of $61.6 million, up 17% year-over-year. OrthoPediatrics reported strong Q1 2026 results with revenue of $59.4 million, up 13% year-over-year, beating estimates, and raised its full-year 2026 revenue outlook to a range of $263.0 million to $267.0 million. Throughout this period, analysts have maintained a predominantly positive sentiment. In the past three months, OrthoPediatrics insiders have sold more company stock than they have bought, with sales totaling $1,003,450.00. The share price as of May 1, 2026, was $15.63, representing a decline of 25.85% from $21.08 on May 5, 2025.

The provided information does not explicitly detail demand seasonality for OrthoPediatrics Corp.'s products and services. However, the company's financial guidance for EBITDA and free cash flow is expected to exhibit similar quarterly seasonality patterns to 2025, implying some level of predictable fluctuation in its financial performance throughout the year. The pediatric orthopedic devices market as a whole is driven by factors such as growing awareness of orthopedic conditions in children, a rise in congenital and developmental disorders, and advancements in device design and materials.

OrthoPediatrics Corp. is a medical device company focused on designing, developing, and marketing orthopedic implants, instruments, and specialized braces for children. Founded in 2006 and headquartered in Warsaw, Indiana, the company operates within the Healthcare sector, specifically the Medical Devices industry. OrthoPediatrics offers a comprehensive portfolio of nearly 90 surgical and bracing systems across three primary categories: trauma and deformity correction, scoliosis procedures, and sports medicine and other pediatric orthopedic needs.

OrthoPediatrics Corp. distributes its products in the United States through a direct sales organization and internationally in over 70 countries via distributors and regional offices across Europe, Latin America, and the Asia-Pacific region. International revenue represented 24% of total revenue in the first quarter of 2026.

OrthoPediatrics maintains a strong brand reputation within its niche as the only publicly traded company exclusively dedicated to the pediatric orthopedic market. The company has consistently delivered strong financial results, with 15% revenue growth in 2025 and projected 11-13% growth for 2026. Continuous investment in R&D and the launch of new product lines enhance its reputation for addressing unmet needs in pediatric orthopedics. Achieving EUMDR certification for Response Spine products and related trauma and deformity devices demonstrates a commitment to quality and regulatory compliance. The company highlights its mission of improving the lives of children, having helped over 1.3 million children since its inception and over 45,000 children in Q1 2026 alone.

OrthoPediatrics Corp. has a significant portion of its shares held by institutional investors (64.53%) and insiders (87.91%). Major institutional owners include Brown Advisory Inc., Millennium Management Llc, BlackRock, Inc., Morgan Stanley, Wellington Management Group Llp, Vanguard Group Inc., Dimensional Fund Advisors Lp, Soleus Capital Management, L.P., Brown Capital Management Llc, Squadron Capital LLC, State Street Corp., Harbor Capital Advisors, Inc., Ronald Blue Trust, Inc., and Ra Capital Management, L.p. The largest individual shareholder is David R. Pelizzon, owning 13.84 million shares, representing 54.74% of the company.